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Abstract
Hydrogen sulfide (H S) is an endogenous gasotransmitter that has vasodilatory properties. It may be a
novel therapy for intestinal ischemia-reperfusion (I/R) injury. We hypothesized that 1) H S would improve
postischemic survival, mesenteric perfusion, mucosal injury, and inflammation compared with vehicle and
2) the benefits of H S would be mediated through endothelial nitric oxide. C57BL/6J wild-type and
endothelial nitric oxide synthase knockout (eNOS KO) mice were anesthetized, and a midline laparotomy
was performed. Intestines were eviscerated, the small bowel mesenteric root identified, and baseline
intestinal perfusion was determined using laser Doppler. Intestinal ischemia was established by temporarily
occluding the superior mesenteric artery. Following ischemia, the clamp was removed, and the intestines
were allowed to recover. Either sodium hydrosulfide (2 nmol/kg or 2 µmol/kg NaHS) in PBS vehicle or
vehicle only was injected into the peritoneum. Animals were allowed to recover and were assessed for
mesenteric perfusion, mucosal injury, and intestinal cytokines. P values < 0.05 were significant. H S
improved mesenteric perfusion and mucosal injury scores following I/R injury. However, in the setting of
eNOS ablation, there was no improvement in these parameters with H S therapy. Application of H S also
resulted in lower levels of intestinal cytokine production following I/R. Intraperitoneal H S therapy can
improve mesenteric perfusion, intestinal mucosal injury, and intestinal inflammation following I/R. The
benefits of H S appear to be mediated through endothelial nitric oxide-dependent pathways.
NEW & NOTEWORTHY H S is a gaseous mediator that acts as an anti-inflammatory agent contributing
to gastrointestinal mucosal defense. It promotes vascular dilation, mucosal repair, and resolution of
inflammation following intestinal ischemia and may be exploited as a novel therapeutic agent. It is unclear
whether H S works through nitric oxide-dependent pathways in the intestine. We appreciate that H S was
able to improve postischemic recovery of mesenteric perfusion, mucosal integrity, and inflammation. The
beneficial effects of H S appear to be mediated through endothelial nitric oxide-dependent pathways.
Keywords: hydrogen sulfide, sodium hydrosulfide, intestinal ischemia, nitric oxide, endothelial nitric
oxide synthase, perfusion, inflammation
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Murine intestinal I/R model.
ංඇඍൾඌඍංඇൺඅ ංඌർඁൾආංൺ continues to be a devastating intra-abdominal emergency with high morbidity and
mortality attributable to the difficult and often late diagnosis. It accounts for over 2% of gastrointestinal
illnesses and is often observed in the setting of abdominal aortic aneurysm surgery, small bowel
transplantation, incarcerated hernias, intestinal volvulus, or following cardiopulmonary bypass (14, 22, 26,
35). If the bowel can be revascularized, patients are often faced with secondary consequences of
reperfusion injury, which can lead to metabolic acidosis, hemodynamic instability, sepsis, and multiple end-
organ dysfunction (29). The mortality from intestinal ischemia can be as high as 65–74% (1, 28).
Present therapies for intestinal ischemia are designed to treat the sequelae of the problem. There are no
medical treatments available that can effectively lessen or potentially reverse the devastating aftermath of
intestinal ischemia. Therefore, a novel therapeutic treatment is essential to aid in improving outcomes in
this patient population. In this regard, the use of hydrogen sulfide (H S) has recently been identified as a
potential therapeutic strategy for gastrointestinal disease. H S donors have been found to be cytoprotective
in the setting of NSAID-induced intestinal injury through modulation of the bile and the microbiome (4, 5).
Additionally, in the setting of colitis, endogenous H S production increases and is found to decrease
following resolution of colitis, and exogenous application also causes significant reduction in the severity
of colitis (33).
H S has also been found to be of benefit in intestinal ischemia-reperfusion (I/R) injury. Preconditioning
with an H S donor before intestinal ischemia has been found to prevent mitochondrial dysfunction by a
BK  channel-dependent mechanism (23). In the postischemic period, application of an H S donor
decreases apoptosis and preserves intestinal architecture (15). Other I/R-related injuries including
myocardial infarction, cerebral ischemia, and transplant-associated renal ischemia were also observed to
receive therapeutic benefit and end-organ protection with use of H S donors (7, 13, 21, 24). H S likely
plays an important role physiologically through cellular signaling and vasodilation. Additionally, it exhibits
anti-inflammatory, antioxidant, and antiapoptotic effects (15, 23, 36). All of these studies support the notion
that the protective properties of H S may be exploited in drug therapy for inflammatory pathology and
specifically in the setting of ischemic injury.
H S may work through endothelial nitric oxide synthase (eNOS) to bring about its protective effects. H S
can donate a sulfur moiety to a cysteine on eNOS, which then promotes its dimerization (2). Only once
dimerized can eNOS facilitate the production of NO (11). NO, as a downstream effector, may then promote
vascular dilation (30). Other studies on coronary artery physiology have suggested that H S may exert its
effects through both NO-dependent and NO-independent pathways, depending on native vascular tonicity
(32). Testai et al. (32) specifically demonstrated that in normotensive rats, H S worked through NO-
dependent pathways, but in hypertensive rats, H S mediated its effects through NO-independent pathways.
Presently, there is no clear understanding of how H S mediates its protective effects in the intestinal
mesenteric vascular bed. Therefore, before H S therapy is used in a clinical setting, the downstream
pathways of this novel treatment must be further elucidated. We hypothesized that 1) H S would improve
postischemic survival, mesenteric perfusion, intestinal mucosal injury scores, and intestinal inflammation
more effectively compared with vehicle following intestinal I/R and 2) the benefits of H S therapy would
be mediated through eNOS-dependent pathways.
MATERIALS AND METHODS
Experimental protocols and animal use were approved by the Indiana
University Institutional Animal Care and Use Committee. Wild-type (WT) adult male mice (C57BL/6J,
stock no: 00664, 8–12 wk, 20–30 g; Jackson, Bar Harbor, ME) and eNOS KO mice (B6.129P2-
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new environment before experimentation. Mice were provided normal chow and water and kept in 12-
h:12-h light-dark cycle housing.
Mice were anesthetized using 3% isofluorane, followed by maintenance at 1.5% isofluorane in oxygen. A
heating pad was used to achieve temperature homeostasis, and the abdomen was prepped using a hair
removal lotion followed by sterile preparation with 70% ethanol and betadine. To account for intraoperative
fluid losses, 1 ml of 0.9% normal saline was injected subcutaneously preoperatively. All animals were
given analgesia (1 mg/kg buprenorphine and 5 mg/kg carprofen) by subcutaneous injection preoperatively.
Under sterile conditions, a midline laparotomy was performed, and the intestines were eviscerated. The
base of the superior mesenteric artery was identified and clamped using an atraumatic microvascular
clamp. The intestines were then placed back into the abdominal cavity, and the abdomen was temporarily
closed using silk suture to prevent evaporative losses. Following 60 min of intestinal ischemia, the
abdomen was reopened, and the atraumatic clamp was removed. The abdominal fascia and skin were then
closed in a two-layer fashion with silk suture. Before complete abdominal closure, the animals underwent
intraperitoneal injection with 250 µl of PBS (vehicle control) or 250 µl of sodium hydrosulfide (NaHS) at
doses of 2 nmol/kg (1.12 × 10  mg/kg) or 2 µmol/kg (1.12 × 10  mg/kg) in PBS. Triple antibiotic
ointment was applied to the abdominal incision following complete closure. Following surgery, animals
were placed in a cage on a heating pad and allowed to awaken. Once fully recovered, animals were
returned to animal housing.
Animals were assigned to the perfusion protocol (n = 10 per vehicle group, 8 per each
NaHS-treated group) as follows: 1) WT IR + vehicle, 2) WT IR + 2 nmol/kg NaHS, 3) WT IR + 2 µmol/kg
NaHS, 4) eNOS KO IR + vehicle, 5) eNOS KO IR + 2 nmol/kg NaHS, and 6) eNOS KO IR + 2 µmol/kg
NaHS. Perfusion was analyzed using a laser-Doppler perfusion imager (LDI; Moor Instruments,
Wilmington, DE). Images were acquired at baseline, at the initial clamping of the superior mesenteric
artery, and 24 h after recovery. A region of interest was created around the entirety of exposed intestines to
obtain a flux mean perfusion within this region. Three images were acquired at each time point and
averaged. Perfusion data were expressed as a percentage of baseline (means ± SE). After the 24-h recovery
analysis, animals were euthanized with isofluorane overdose and cervical dislocation, and intestinal tissues
were explanted for further analyses.
Intestinal tissues were harvested following euthanasia of experimental groups.
Terminal ileums were then fixed using 4% paraformaldehyde with subsequent dehydration in 70% ethanol.
Intestines were paraffin embedded, sectioned, and subsequently stained with hematoxylin and eosin. A
histological scoring method of intestinal damage was used as previously described: 0, no damage; 1,
subepithelial space at the villous tip; 2, loss of mucosal lining at the villous tip; 3, loss of less than half of
the villous structure; 4, loss of more than half of the villous structure; and 5, transmural necrosis (8, 34).
All histological sections were evaluated by two blinded authors (A. Jensen, N. Drucker), and scores were
averaged.
Following euthanasia, mouse intestinal tissues designated for protein
analysis were harvested, snap frozen in liquid nitrogen, and stored at −80°C. Once ready to use, intestines
were thawed and homogenized in RIPA buffer (Sigma, St. Louis, MO) with phosphatase and protease
inhibitors (1:100 dilution, Sigma) using a Bullet Blender tissue homogenizer (Next Advance, Averill Park,
NY). Following homogenization, samples were centrifuged at 12,000 revolution/min to pellet extraneous
tissue, and supernatants were collected and placed into fresh Eppendorf tubes. Total protein concentration
was quantified with the Bradford assay using a spectrophotometer (VersaMax microplate reader; Molecular
Devices, Sunnyvale, CA).
Murine intestinal levels of interleukin 6 (IL-6), IL-9, IL-10, C-X-C ligand 10 (IP10), macrophage
−4 −1
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Statistical analysis.
NaHS improves intestinal perfusion following I/R injury through eNOS-dependent pathways.
NaHS prevents mucosal injury following I/R through eNOS-dependent pathways.
NaHS attenuates the intestinal inflammatory cytokine response following I/R injury.
inflammatory protein 2 (MIP-2), granulocyte-colony stimulating factor (G-CSF), MIP-1α, eotaxin, vascular
endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), hepatocyte growth factor (HGF),
and C-X-C ligand 1 (KC) were quantified using a Bio-Plex 200 multiplex beaded assay system (Bio-Rad,
Hercules, CA) with customizable multiplex plates for murine inflammatory cytokines (Millipore, Billerica,
MA). Assays were performed at 1:20 dilution according to the manufacturer’s instructions and are reported
in nanograms of cytokine per gram of total intestinal protein (means ± SE).
All statistical analysis was performed using GraphPad Prism 7 (GraphPad Software,
La Jolla, CA). Perfusion, histology, and cytokine analysis were reported as means ± SE and compared
using the Mann-Whitney U-test for nonparametric variables. P values < 0.05 were considered statistically
significant.
RESULTS
Intestinal perfusion was compared in treatment groups at 24 h following I/R injury (Fig. 1). Low- and high-
dose NaHS treatment promoted significantly improved postischemic perfusion levels (78.3 ± 7.3%, 63.4 ±
7.2%) compared with vehicle (26.4 ± 5.3%; P = 0.0002, P = 0.003, respectively) in WT animals assessed at
24 h following injury. Conversely, in eNOS KO mice, perfusion was similar among treated and untreated
groups, and no significant differences were found between vehicle (34.4 ± 6.6%), 2 nmol/kg NaHS (32.1 ±
6.9%), or 2 µmol/kg NaHS (52.7 ± 9.2%) groups (P = 0.72 and P = 0.33, respectively).
Significant
sloughing of intestinal mucosa and destruction of the epithelial layer in the crypt-villous architecture was
seen in PBS vehicle-treated WT groups (3.20 ± 0.30) compared with WT mice treated with 2 nmol/kg
NaHS (1.30 ± 0.25, P < 0.0001) or 2 µmol/kg NaHS (1.60 ± 0.29, P = 0.002). No significant improvements
were seen in histological injury with NaHS therapy in eNOS KO animals (Fig. 2).
Intestinal
cytokines and growth factors were affected by H S therapy following ischemic injury. IL-6 was noted to be
significantly decreased in WT intestines exposed to both 2 nmol/kg and 2 µmol/kg NaHS, whereas IL-9,
IL-10, VEGF, and FGF-2 were only lowered by the 2 µmol/kg dose of NaHS (Fig. 3). In murine animals
with eNOS KO, although decreases in IL-9, IL-10, and VEGF were observed, they did not reach statistical
significance. IL-6 and FGF-2 were the only two cytokines to have significant decreases in chemokine
production. IL-6 significantly decreased with 2 µmol/kg NaHS treatment, and FGF-2 significantly
decreased with 2 nmol/kg NaHS treatment. HGF was not affected in this model system by NaHS or with
eNOS ablation.
Inflammatory chemokines in the intestinal segments were also affected by NaHS following injury (Fig. 4).
MIP-1α, eotaxin, and IP-10 were significantly decreased only in the 2 µmol/kg-treated groups, whereas
there was no effect on these factors with the lower doses of NaHS in WT intestinal segments. Levels of
MIP-2, G-CSF, and KC were significantly decreased in intestines with both tested doses of NaHS. Lastly,
in evaluation of cytokines from NaHS-treated intestines from eNOS KO animals, there were no significant
differences compared with the vehicle-treated group.
DISCUSSION
Intestinal ischemia is a devastating abdominal emergency. Many times necrotic intestine needs to be
surgically excised, which can leave patients with an inadequate amount of bowel to promote normal
nutrient absorption. Present therapies are inadequate at protecting ischemic intestine, and, therefore, novel
therapies are being explored. Herein we observed that H S treatment (in the form of NaHS) following I/R
2
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injury can provide gastrointestinal protection. These beneficial properties appear to be mediated, in part, by
eNOS.
We observed improvements in mesenteric perfusion and preservation of intestinal mucosal integrity and
decreased inflammation following ischemic insult. However, although we did observe significant benefits
with NaHS therapy following intestinal ischemia, these beneficial properties were not observed in the
absence of eNOS. Similarly, Coletta et al. (9) previously reported that H S-induced angiogenesis requires
NO biosynthesis and inhibition of eNOS abolished the H S-stimulated angiogenic response. Their research
suggested that NO and H S worked synergistically to increase cGMP production, cGMP-dependent protein
kinase G activation, and angiogenesis. Additionally, in their studies, the vasorelaxant action of H S also
required the presence of endogenously produced NO, further confirming the significant complexity of
biological interactions between these two gasotransmitters.
In this study, we observed equivalent rates of improvement in mesenteric perfusion with the addition of
both low and high doses of NaHS. These improvements in perfusion were lost when eNOS was genetically
ablated. Intestinal mucosal injury was also improved with NaHS therapy. Although it is possible that H S
can directly preserve intestinal mucosal integrity by limiting inflammation and apoptosis (15, 23, 36), it is
also equally likely that the main effects of H S therapy are to promote vasodilation (3) and improve
mesenteric blood flow. Better intestinal reperfusion after injury in itself will limit further mucosal damage
and intestinal inflammation. Furthermore, if the effects of H S were solely on the intestinal epithelium,
then knocking out eNOS should not have had an effect on host preservation.
Significant elevations in intestinal chemokines, including MIP, eotaxin, and chemokine ligand 10 (IP-10)
have been noted following intestinal ischemia and are thought to be responsible for leukocyte mobilization
to the areas of injured bowel (17, 31). These cells are responsible for injury repair but also promote
inflammation, which may be detrimental to the host. For example, lymphocyte influx is thought to be
detrimental to recovery, as lymphocyte-depleted animals had better outcomes following intestinal ischemia
(6). However, other leukocyte classes may actually promote intestinal recovery by digesting dead cells and
repairing the extracellular matrix (27). Additionally, markers of neovascularization have been elevated after
intestinal ischemia (10, 16). Neovasculogenesis increases intestinal capillary density to restore oxygen
balance and nutrient homeostasis to injured bowel.
In a similar fashion, we also appreciated a significant decrease in intestinal chemokines. High-dose NaHS
(2 µmol/kg) decreased MIP-1α, eotaxin, and IP-10 levels, whereas both low- and high-range doses
significantly decreased intestinal MIP-2, G-CSF, and KC levels. Although we observed lower levels of
several chemokines in eNOS KO animals following NaHS therapy, none of these reached statistical
significance. Therefore, H S-mediated decreases in all assessed chemokines following intestinal ischemia
appeared to be dependent on the presence of eNOS.
We also observed a significant decrease in several inflammatory cytokines and growth factors after NaHS
therapy. IL-6, IL-9, IL-10, VEGF, and FGF-2 were all decreased after NaHS therapy although only IL-6
was noted to be decreased at both the 2 nmol/kg and 2 µmol/kg concentrations. HGF was not impacted by
NaHS therapy. Although decreases in IL-9, IL-10, and VEGF appeared to be dependent on functioning
eNOS, production of IL-6 appeared to also decrease in the mid-range dose for eNOS KO animals, and
FGF-2 appeared to decrease in the low-range NaHS-treated eNOS KO animals. HGF was also not affected
by ablation of eNOS. These findings would indicate that many of the inflammatory factors tested, but
certainly not all of them, were impacted by the presence of functional eNOS. On the basis of the data
presented herein, we surmise that the presence of eNOS promotes H S-mediated improvements in vascular
tonicity. Because of better mesenteric perfusion, injured intestines are able to recover more effectively, and
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Conclusion.
The superior mesenteric artery ligation model of intestinal I/R does not model clinical intestinal ischemia to
its fullest. Although complete small bowel ischemia is possible secondary to superior mesenteric artery
thrombus or embolus, the majority of intestinal ischemic episodes are due to segmental intestinal ischemia,
such as may be seen with adhesive bowel obstructions or incarcerated hernias. Nonetheless, this model
mimics the most severe form of intestinal ischemia and, therefore, is likely considered the best animal
model available to test the effectiveness of novel therapies.
In conclusion, H S appears to be a novel therapeutic agent for the treatment of intestinal I/R
injury. The beneficial effects of improved mesenteric perfusion, histological injury, and inflammatory
cytokine and chemokine modulation appear to be mediated through eNOS. Additional modes of delivery,
including inhaled delivery systems, need to be tested with this model to determine the best clinical
application. These factors, as well as the effects of H S on long-term survival and neurodevelopment, need
to be assessed before widespread clinical implementation.
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Fig. 1.
Hydrogen sulfide (H S) improves mesenteric perfusion following ischemic injury through endothelial nitric oxide synthase
(eNOS)-dependent pathways. Postischemic mesenteric perfusion was significantly increased with both low- and high-
range doses of sodium hydrosulfide (NaHS) in wild-type (WT) animals. However, there were no observed improvements
in postischemic mesenteric perfusion following treatment in eNOS knockout (KO) animals (*P < 0.05 vs. respective
vehicle).
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Fig. 2.
Histological examination of small intestine following intestinal ischemia and reperfusion (I/R). A: representative histology
slides of each treatment group (hematoxylin and eosin stain, ×20) demonstrating improvements in intestinal histology with
NaHS therapy in WT animals but not in eNOS KO animals. B: histological scoring of intestinal specimens (*P < 0.05 vs.
respective vehicle).
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Fig. 3.
Inflammatory cytokines and growth factors are impacted by H S therapy following intestinal I/R. Intestinal levels of IL-6,
IL-9, IL-10, VEGF, and fibroblast growth factor 2 (FGF-2) are decreased with H S therapy following intestinal ischemia.
H S decreases in IL-9, IL-10, and VEGF appear to be facilitated by intact eNOS, whereas decreases in IL-6 and FGF-2
may work through H S-independent pathways. Hepatocyte growth factor (HGF) does not appear to be affected by H S
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Fig. 4.
Chemokines are impacted by H S therapy following intestinal I/R. Intestinal levels of macrophage inflammatory protein
1α (MIP-1α), eotaxin, chemokine ligand 10 (IP-10), MIP-2, granulocyte-colony stimulating factor (G-CSF), and C-X-C
ligand 1 (KC) are decreased in ischemic intestines following H S therapy. Levels of these factors were not impacted
significantly by genetic ablation of eNOS (*P < 0.05 vs. WT vehicle).
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